Skip to main content
SpringerLink
Log in

Psychopharmaka

  • Chapter
Arzneiverordnungs-Report 2007

Auszug

Die Verordnungsstruktur der Psychopharmaka hat sich in den letzten 10 Jahren auffällig verändert. Die Verordnungen der früher führenden Tranquillantien sind seit vielen Jahren rückläufig. Umgekehrt haben sich die Antidepressivaverordnungen in dieser Zeit mehr als verdoppelt. Dieser Trend setzte sich 2006 durch einen im Mittel diesmal nur mäßigen Anstieg bei den selektiv wirkenden Antidepressiva fort. Auch die Verordnung von Neuroleptika ist im Bereich der atypischen Neuroleptika unter anderem durch Indikationsausweitungen angestiegen. Beträchtlich zugenommen haben wiederum die Verordnungen von Psychostimulantien einschließlich des neu eingeführten Atomoxetins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Diabetes Association et al. (2004): Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596–601.

    Article  Google Scholar 

  • Anderson IM (2000): Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58: 19–36.

    Article  PubMed  CAS  Google Scholar 

  • Anonym (2003): Lithium-Therapie bei der manisch-depressiven Erkrankung: Immer noch der Standard? Arzneimittelbrief 37: 49–51.

    Google Scholar 

  • Anonym (2004): Escitalopram. Un isomère du citalopram, sans aucun avantage thérapeutique. Rev Prescrire 24: 325–328.

    Google Scholar 

  • Anonym (2005a): Antidepressiva: lebensgefährliche Placebos? Arznei-telegramm 36: 45–47.

    Google Scholar 

  • Anonym (2005b): Aripiprazole. Prescrire Int 14: 163.

    Google Scholar 

  • Anonym (2006a): Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int 15: 168–172.

    Google Scholar 

  • Anonym (2006b): Neuroleptics: increased rate of venous thromboembolic events. Rev. Prescrire Internat 15: 224.

    Google Scholar 

  • Anonym (2006c): SSRI antidepressants and birth defects. Prescrire Int 15: 222–223.

    Google Scholar 

  • Apter JT, Allen LA (1999): Buspirone: future directions. J Clin Psychopharmacol 19: 86–93.

    Article  PubMed  CAS  Google Scholar 

  • Arvanitis LA, Miller BG (1997): Multiple fixed doses of „Seroquel“ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42: 233–246.

    Article  PubMed  CAS  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2003): Empfehlungen zur Therapie von Angst-und Zwangsstörungen. 2. Aufl. Sonderheft Arzneiverordnung in der Praxis.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2006a): Empfehlungen zur Therapie der Depression. 2. Aufl. Sonderheft Arzneiverordnung in der Praxis, im Druck.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2006b): UAW-News — International. Hyponatriämie unter Escitalopram. Deutsches Ärzteblatt 103: C358.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2006c): Hypersexualität unter Aripiprazol. Deutsches Ärzteblatt 103: A3518.

    Google Scholar 

  • Baghai TC, Volz HP, Möller HJ (2006): Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 7: 198–222.

    Article  PubMed  Google Scholar 

  • Barbui C, Hotopf M (2001): Amitriptyline vs. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Brit J Psychiatry 178: 129–144.

    Article  CAS  Google Scholar 

  • Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP et al (2000): Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000 (4): CD002791.

    Google Scholar 

  • Bauer M, Dopfner S (1999): Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19: 427–434.

    Article  PubMed  CAS  Google Scholar 

  • Bauer M, Grof P, Müller-Oerlinghausen B (eds.) (2006) Lithium in Neuropsychiatry: The Comprehensive Guide. Taylor & Francis Books Ltd, Abingdon, (in print)

    Google Scholar 

  • Bauer M, Whybrow PC, Angst C, Verslani M, Möller H-J (2002): World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3: 5–43.

    Article  PubMed  Google Scholar 

  • Baumann P (1996): Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31: 444–469.

    Article  PubMed  CAS  Google Scholar 

  • Baumann P, Zullino DF, Eap CB (2002): Enantiomers’ potential in psychopharmacology — a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 12: 433–444.

    Article  PubMed  CAS  Google Scholar 

  • Benkert O, Szegedi A, Kohnen R (2000): Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61: 656–663.

    PubMed  CAS  Google Scholar 

  • Bielski RJ, Ventura D, Chang CC (2004): A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65: 1190–1196.

    PubMed  CAS  Google Scholar 

  • Bonnet U (2003): Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 9: 97–140.

    PubMed  CAS  Google Scholar 

  • Braun M, Strasser RH (1997): Trizyklische Antidepressiva und kongestive Kardiomypathie. Internist 38: 1236–1238.

    PubMed  CAS  Google Scholar 

  • Carriere P, Bonhomme D, Lemperiere T (2000): Amisulpride has a superior benefit/ risk profile to haloperidol in schizophrenia: results of a multicentre, doubleblind study (the Amisulpride Study Group). Eur Psychiatry 15: 321–329.

    Article  PubMed  CAS  Google Scholar 

  • Carter CS, Mulsant BH, Sweet RA, Maxwell RA, Coley K et al (1995): Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacol Bull 31: 719–725.

    PubMed  CAS  Google Scholar 

  • Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MW, Louik C, Lyons Jones K et al (2006): Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354: 579–587.

    Article  PubMed  CAS  Google Scholar 

  • Chick J, Howlett H, Morgan MY, Ritson B (2000): United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35: 176–187.

    PubMed  CAS  Google Scholar 

  • Chouinard G, Jones B, Remington G, Bloom D, Addington D et al (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25–40.

    Article  PubMed  CAS  Google Scholar 

  • Cipriani A, Pretty H, Hawton K, Geddes JR (2005): Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162: 1805–1819.

    Article  PubMed  Google Scholar 

  • Correll CU, Leucht S, Kane JM (2004): Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161: 414–425.

    Article  PubMed  Google Scholar 

  • Csernansky JG, Mahmoud R, Brenner R (2002): A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16–22.

    Article  PubMed  CAS  Google Scholar 

  • Davis JM, Chen N, Glick ID (2003): A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553–564.

    Article  PubMed  CAS  Google Scholar 

  • De Abajo FJ, Rodriguez LAG, Montero D (1999): Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Brit Med J 319: 1106–1109.

    PubMed  Google Scholar 

  • Di Carlo G, Borreli F, Ernst E, Izzo AA (2001): St John’s wort: Prozac from the plant kingdom. Trends Pharmacol Sci 22: 292–297.

    Article  PubMed  Google Scholar 

  • Dinan TG (2002): Lithium in bipolar mood disorder. Evidence suggests that lithium should still be first choice for prophylactic treatment. Brit Med J 324: 988–989.

    Article  Google Scholar 

  • Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K et al (2000): Deliberate self-harm and antidepressant drugs. Investigation of a possible link. Br J Psychiatry 177: 551–556.

    Article  PubMed  CAS  Google Scholar 

  • Doraiswamy PM, Schott G, Star K, Edwards R, Müller-Oerlinghausen B (2006): Atypical antipsychotics and pituitary tumors in the WHO database. Posterpräsentation, APA, Toronto, Canada.

    Google Scholar 

  • Einarson TR, Arikian SR, Casciano J, Doyle JJ (1999): Comparison of extendedrelease venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 21: 296–308.

    Article  PubMed  CAS  Google Scholar 

  • Elliger TJ, Trott GE, Nissen G (1990): Prevalence of psychotropic medication in childhood and adolescence in the Federal Republic of Germany. Pharmacopsychiatry 23: 38–44.

    PubMed  CAS  Google Scholar 

  • El-Zein RA, Abdel-Rahman SZ, Hay MJ, Lopez MS, Bondy ML, Morris DL et al (2005): Cytogenetic effects in children treated with methylphenidate. Cancer Lett 230: 284–291.

    Article  PubMed  CAS  Google Scholar 

  • EMEA (2005): Scientific Discussion vom 27.1.2005. Im Internet unter: www.emea. eu.int/humandocs/Humans/EPAR/cymbalta/cymbalta.htm

    Google Scholar 

  • Ernst CL, Goldberg JF (2004): Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 12: 14–41.

    PubMed  Google Scholar 

  • Food and Drug Administration (FDA) (2007): FDA proposes new warnings about suicidal thinking, behaviour in young adults to take antidepressant medications. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html.

    Google Scholar 

  • Franchini L, Zanardi R, Gasperini M, Perez J, Smeraldi E (1996): Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. J Affect Disord 38: 67–69.

    Article  PubMed  CAS  Google Scholar 

  • Frank E, Kupfer DJ, Perel JM (1990): Three-years outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47: 1093–1099.

    PubMed  CAS  Google Scholar 

  • Friedman RA (2006): The changing face of teenage drug abuse — the trend toward prescription drugs. N Engl J Med 354: 1448–1450.

    Article  PubMed  CAS  Google Scholar 

  • Gale C, Oakley-Browne M (2000): Anxiety disorder. Brit Med J 321: 1204–1207.

    Article  PubMed  CAS  Google Scholar 

  • Geddes J, Freemantle N, Harrison P et al (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321: 1371–1376.

    Article  PubMed  CAS  Google Scholar 

  • Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library — Issue1.

    Google Scholar 

  • Gentile S (2007): Atypical antipsychotics for the treatment of bipolar disorders. CNS Drugs 21: 367–387.

    Article  PubMed  CAS  Google Scholar 

  • Giles J (2007): Court case to reclain confidential data. Nature 446: 838–839.

    Article  PubMed  CAS  Google Scholar 

  • Goodnick PJ, Barrios CA (2001): Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin Pharmacother 2: 667–680.

    Article  PubMed  CAS  Google Scholar 

  • Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003): Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467–1473.

    Article  PubMed  CAS  Google Scholar 

  • Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S et al (2004): A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65: 432–441.

    PubMed  CAS  Google Scholar 

  • Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A et al (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40: 179–190.

    Article  PubMed  CAS  Google Scholar 

  • Guelfi JD, Ansseau M, Timmerman L, Korsgaard S (2001): Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 21: 425–431.

    Article  PubMed  CAS  Google Scholar 

  • Gunnel D, Ashby D (2004): Antidepressants and sucide: what is the balance of benefit and harm. BMJ 329: 34–38.

    Article  Google Scholar 

  • Healy D (2003): Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72: 71–79.

    Article  PubMed  Google Scholar 

  • Hirschfeld RM, Kasper S (2004): A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 7: 507–522.

    Article  PubMed  CAS  Google Scholar 

  • Hoffmann F, Glaeske D, Scharffetter W (2006): Zunehmender Hypnotikaverbrauch auf Privatrezepten in Deutschland. Sucht 52: 360–366.

    Google Scholar 

  • Hypericum Depression Trial Study Group (2002): Effect of Hypericum perforatum (St John’s Wort) in major depressive disorder. JAMA 287: 1807–1814.

    Article  Google Scholar 

  • Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006): Randomized controlled trial of the effect on Quality of Life of secondvs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079–1087.

    Article  PubMed  CAS  Google Scholar 

  • Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL (2004): Efficacy and safety of antidepressants for children and adolescents. BMJ 328: 879–883.

    Article  PubMed  CAS  Google Scholar 

  • Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA (2006): The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163: 813–821.

    Article  PubMed  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796.

    PubMed  CAS  Google Scholar 

  • Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003): Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125–1132.

    Article  PubMed  Google Scholar 

  • Kappler J, Menges C, Ferbert A, Ebel H (1994): Schwere “Spät” dystonie nach “Neuroleptanxiolyse” mit Fluspirilen. Nervenarzt 65: 66–68.

    PubMed  CAS  Google Scholar 

  • Kasper S (1996): Mirtazapin. Klinisches Profil eines noradrenalin-und serotoninspezifischen Antidepressivums. Arzneimitteltherapie 14(9): 257–259.

    Google Scholar 

  • Kassenärztliche Bundesvereinigung (2006): Wirkstoff aktuell: Quetiapin (Seroquel®). Ausgabe 05/2006.

    Google Scholar 

  • Kessler RC, Demier O, Frank RG, Olfson M, Pincus HA, Walters EE et al (2005): Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 352:2515–2523.

    Article  PubMed  CAS  Google Scholar 

  • Kimko HC, Cross JT, Abernethy DR (1999): Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmakokinet 37: 457–470.

    Article  CAS  Google Scholar 

  • Knopf H, Melchert H-U (2003): Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Robert-Koch-Institut Berlin (Hrsg).

    Google Scholar 

  • Knuppel L, Linde K (2004): Adverse effects of St. John’s Wort: a systematic review. J Clin Psychiatry 65: 1470–1479.

    PubMed  Google Scholar 

  • Kornhuber J (1994): Potentielle Antipsychotica mit neuartigen Wirkmechanismen. In: Riederer P, Laux G, Pöldinger W (Hrsg): Neuropsychopharmaka, Bd. 4: Neuroleptica. Springer-Verlag, Wien New York, S. 185–196.

    Google Scholar 

  • Lapierre YD (1989): A review of trimipramine 30 years of clinical use. Drugs 38(suppl 1): 17–24.

    PubMed  Google Scholar 

  • Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B et al (2001): The European acamprosate trials. Conclusions for research and therapy. J Biomed Sci 8: 89–95.

    Article  PubMed  CAS  Google Scholar 

  • Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003a): Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160: 1209–1222.

    Article  PubMed  Google Scholar 

  • Leucht S, Wahlbeck K, Hamann J, Kissling W (2003b): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361: 1581–1589.

    Article  PubMed  CAS  Google Scholar 

  • Leucht S, Komossa K (2006): Methodik und kritische Interpretation psychopharmakologischer Schizophreniestudien. Psychopharmakotherapie 13: 231–240.

    Google Scholar 

  • Licino J, Wong M-L (2005): Depression, antidpressants and sucidality: a critical appraisal. Nature Rev. Drug Disc. 4, 165–171.

    Article  CAS  Google Scholar 

  • Liebermann JA, Stroup TS, McEvoy JP et al or the CATIE Investigators (2005): Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1233.

    Google Scholar 

  • Linde K, Berner M, Egger M, Mulrow C (2005): St John’s wort for depression: metaanalysis of randomised controlled trials. Br J Psychiatry 186: 99–107.

    Article  PubMed  Google Scholar 

  • MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F et al (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit Med J 326: 1014–1019.

    Article  PubMed  CAS  Google Scholar 

  • Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software.

    Google Scholar 

  • Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825–835.

    PubMed  CAS  Google Scholar 

  • McCue RE, Waheed R, Urcuyo L et al (2006): Comparative effectiveness of secondgeneration antipsychotics and haloperidol in acute schizophrenia. Brit J Psychiatry 189: 433–440.

    Article  Google Scholar 

  • McEvoy JP et al. Catie Investigators (2006): Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600–610.

    Article  PubMed  Google Scholar 

  • Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G (2004): Interaction of St John’s wort with conventional drugs: systematic review of clinical trials. BMJ 329: 27–30.

    Article  PubMed  Google Scholar 

  • Molina BSG, Florey K, Hinshaw SP, Greiner, AR, Arnold E, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliot GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007): Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46: 1028–1040.

    Article  PubMed  Google Scholar 

  • Möller H-J (1999): Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4): 99–107.

    PubMed  Google Scholar 

  • Möller H-J, Volz HP, Reimann IW, Stoll KD (2001): Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59–65.

    Article  PubMed  Google Scholar 

  • Moncrieff J (2001): Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis 189: 288–295.

    Article  PubMed  CAS  Google Scholar 

  • Moncrieff J, Kirsch I (2005): Efficacy of antidepressants in adults. BMJ 331: 155–157.

    Article  PubMed  Google Scholar 

  • Montgomery SA, Roberts A, Patel AG (1994): Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharmacology 9: 49–53.

    Article  Google Scholar 

  • Montgomery S, Ferguson JM, Schwartz GE (2003): The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 23: 45–50.

    Article  PubMed  CAS  Google Scholar 

  • MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 56: 1073–1086.

    Article  Google Scholar 

  • Müller-Oerlinghausen B (2001): Abhängigkeit und Mißbrauch von Substanzen. Dtsch Ärztebl 98: A1625–A1627.

    Google Scholar 

  • Müller-Oerlinghausen B, Berghöfer A (1999): Antidepressants and suicidal risk. J Clin Psychiatry 60(suppl 2): S94–S99.

    Google Scholar 

  • Müller-Oerlinghausen B, Berghöfer A, Ahrens B (2003): The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry 48: 433–439.

    PubMed  Google Scholar 

  • Naber D, Dose M (2006): Pro und Kontra: Grundsätzlicher Vorrang für Atypica. Psychiatr Praxis 32: 163–166.

    Google Scholar 

  • Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV (2002): Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36: 106–132.

    PubMed  Google Scholar 

  • Nissen SE (2006): ADHD drugs and cardiovascular risk. N Engl J Med 354:1445–1448.

    Article  PubMed  CAS  Google Scholar 

  • Oeljeschläger B, Müller-Oerlinghausen B (2004): Wege zur Optimierung der individuellen antidepressiven Therapie. Deutsches Ärzteblatt 101: A 1337–1340.

    Google Scholar 

  • Perlis RH, Perlis CS, Wu Y, Hwang M, Nierenberg AA (2005): Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 162: 1957–1960.

    Article  PubMed  Google Scholar 

  • Remschmidt H, Global ADHD Working Group (2005): Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry 14: 127–137.

    Article  PubMed  Google Scholar 

  • Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, Goltzman D, for the Canadian Multicentre Osteoporosis Study (CaMos) Research Group (2007): Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167: 188–194.

    Article  PubMed  CAS  Google Scholar 

  • Rickels K, Rynn M (2002): Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 63(Suppl 14): 9–16.

    PubMed  CAS  Google Scholar 

  • Riederer P, Laux G, Pöldinger W (Hrsg) (1993): Neuropsychopharmaka Bd. 3 Antidepressiva und Phasenprophylaktika. Springer-Verlag, Wien New York.

    Google Scholar 

  • Royal College of Psychiatrists, British Psychological Society (2006): Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. Internet: http://guidance.nice.org.uk/CG1/guidance/pdf/ English

    Google Scholar 

  • Rush AJ et al. STAR*D Investigators Group (2004): Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142.

    Article  PubMed  Google Scholar 

  • Safer DJ (2000): Are stimulants overprescribed for youths with ADHD? Ann Clin Psychiatry 12: 55–62.

    PubMed  CAS  Google Scholar 

  • Sass H, Soyka M, Mann K, Zieglgansberger W (1996): Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53: 673–680.

    PubMed  CAS  Google Scholar 

  • Schöpf J, Müller-Oerlinghausen B (2005): Standardpräparate der Psychopharmakotherapie. Lithium. 2. Aufl. Springer-Verlag, Berlin Heidelberg New York

    Google Scholar 

  • Schou M (1998): Has the time come to abandon prophylactic lithium treatment? A reviewfor clinicians. Pharmacopsychiatry 31: 210–215.

    Article  PubMed  CAS  Google Scholar 

  • Schreiber S, Pick CG (2006): From selective tio highly selective SSRIs: A comparison of the antinociceptive properties of fluoxetine, fluvoxamine, citalopram and escitalopram. Eur Neuropsychopharmacol 16: 464–468.

    Article  PubMed  CAS  Google Scholar 

  • Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME et al (2001): Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA 285: 1978–1986.

    Article  PubMed  CAS  Google Scholar 

  • Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002): Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396–404.

    Article  PubMed  Google Scholar 

  • Snow V, Lascher S, Mottur-Pilson C, for the American College of Physicians — American Society of Internal Medicine (2000): Clinical guideline I. Pharmacological treatment of acute major depression and dysthymia. Ann Int Med 132: 739–742.

    Google Scholar 

  • Sobanski E (2006): Medikamentöse Therapie der Aufmerksamkeitsdefizi-/Hyperaktivitätsstörung (ADHS) bei Erwachsenen. Psychopharmakotherapie 13: 100–106.

    Google Scholar 

  • Sramek JJ, Zarotsky V, Cutler NR (2002): Generalized anxiety disorder: treatment options. Drugs 62: 1635–1648.

    Article  PubMed  CAS  Google Scholar 

  • Stip E (2000): Novel antipsychotics: issues and controversies. Typicality of atypical neuroleptics. J Psychiatry Neurosci 25: 137–153.

    PubMed  CAS  Google Scholar 

  • Stroup TS et al. CATIE Investigators (2006): Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611–622.

    Article  PubMed  Google Scholar 

  • Swift RM (1999): Drug therapy for alcohol dependence. N Engl J Med 340: 1482–1490.

    Article  PubMed  CAS  Google Scholar 

  • Szarfman A, Tonning JM, Levine JG, Doraiswamy PM (2006): Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 26: 748–758.

    Article  PubMed  CAS  Google Scholar 

  • Tandon R, Jibson MD (2003): Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26.

    Article  PubMed  CAS  Google Scholar 

  • Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000): Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35: 202–209.

    PubMed  CAS  Google Scholar 

  • Thase ME (2003): Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 64(Suppl 2): 3–7.

    CAS  Google Scholar 

  • Thase ME, Entsuah R, Rudolph RL (2001): Remission rates during treatment with venlafaxine or selective reuptake inhibitors. Br J Psychiatry 178: 234–241.

    Article  PubMed  CAS  Google Scholar 

  • Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA et al (2004): Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. Br J Psychiatry 184: 337–345.

    Article  PubMed  Google Scholar 

  • Trindade E, Menon D, Topfer LA, Coloma C (1998): Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a metaanalysis. Canad Med Ass J 159: 1245–1252.

    CAS  Google Scholar 

  • Trivedi MH et al. STAR*D Study Team (2006a): Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28–40.

    Article  PubMed  Google Scholar 

  • Van Walraven C, Mamdani MM, Wells PS, Williams JI (2001): Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. Brit Med J 323: 1–6.

    Article  Google Scholar 

  • Volovka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP et al (2004): Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65: 57–61.

    Article  Google Scholar 

  • Volz HP, Gleiter CH, Möller HJ (1996): Monoaminoxidasehemmer in der Psychiatrie. Nervenarzt 67: 339–347.

    PubMed  CAS  Google Scholar 

  • Volz HP, Möller HJ, Reimann I, Stoll K (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuropsychopharmacol 10: 211–217.

    Article  PubMed  CAS  Google Scholar 

  • Walsh BT, Scidman SN, Sysko R, Gould M (2002): Placebo response in studies of major depression. Variable, substantial and growing. JAMA 287: 1840–1847.

    Article  PubMed  Google Scholar 

  • Weinmüller B (2004): Die neuroleptische Therapie schizophrener Psychosen: eine naturalistische retrospective Untersuchung zur Behandlungswirklichkeit in einem Krankenhaus mit Vollversorgungsauftrag. Med Dissertation an der TU München. Angenommen am 15.12.2004.

    Google Scholar 

  • Wetterling T (2001): Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24: 59–73.

    Article  PubMed  CAS  Google Scholar 

  • Whittington CJ, Kendall T, Fonagy P, Cottrell D, Colgrove A, Boddington E (2004): Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363: 1341–1345.

    Article  PubMed  CAS  Google Scholar 

  • Williams JW Jr, Mulrow CD, Chiquette E, Hitchcock Noël P, Aguilar C, Cornell J (2000): Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 132: 743–756.

    PubMed  CAS  Google Scholar 

  • Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004): Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol 18: 262–276.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie und Toxikologie der Universität Würzburg, Versbacher Straße 9, 97078, Würzburg

    Prof. Dr. med. Martin J. Lohse

  2. Uferstraße 1, 69168, Wiesloch

    Privatdozentin Dr. med. Anna Lorenzen

  3. Bartningallee 11-13, 1055, Berlin

    Prof. Dr. med. Bruno Müller-Oerlinghausen

Authors
  1. Prof. Dr. med. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Privatdozentin Dr. med. Anna Lorenzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. Bruno Müller-Oerlinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Lohse, M.J., Lorenzen, A., Müller-Oerlinghausen, B. (2008). Psychopharmaka. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72548-0_42

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72547-3

  • Online ISBN: 978-3-540-72548-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation